Advanced search
Publication Cover
Expert Review of Clinical Immunology Volume 4, 2008 - Issue 2
Submit an article Journal homepage
51
Views
18
CrossRef citations to date
0
Altmetric
Review

Novel approaches in the management of refractory celiac disease

Wieke HM Verbeek VU University Medical Center, Department of Gastroenterology and Hepatology, PO Box 7057, 1007 MB, Amsterdam, The Netherlands. [email protected]
,
Marco WJ Schreurs VU University Medical Center, Department of Pathology, Medical Immunological Laboratory, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands. [email protected]
,
Otto J Visser VU University Medical Center, Department of Hematology, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands. [email protected]
,
B Mary E von Blomberg VU University Medical Center, Department of Pathology, Medical Immunological Laboratory, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands. [email protected]
,
Abdulbaqi Al-Toma St Antonius Hospital, Department of Gastroenterology and Hepatology, PO Box 2500, 3430 EM, Nieuwegein, The Netherlands. [email protected]
&
Chris JJ Mulder VU University Medical Center, Department of Gastroenterology and Hepatology, PO Box 7057, 1007 MB, Amsterdam, The Netherlands. [email protected]
Pages 205-219 | Published online: 10 Jan 2014

References

  • Dube C, Rostom A, Sy R et al. The prevalence of celiac disease in average-risk and at-risk Western European populations: a systematic review. Gastroenterology128(4 Suppl. 1), S57–S67 (2005).
  • Fasano A, Catassi C. Current approaches to diagnosis and treatment of celiac disease: an evolving spectrum. Gastroenterology120(3), 636–651 (2001).
  • Green PH. The many faces of celiac disease: clinical presentation of celiac disease in the adult population. Gastroenterology128(4 Suppl. 1), S74–S78 (2005).
  • Wahab PJ, Meijer JW, Mulder CJ. Histologic follow-up of people with celiac disease on a gluten-free diet: slow and incomplete recovery. Am. J. Clin. Pathol.118(3), 459–463 (2002).
  • Daum S, Cellier C, Mulder CJ. Refractory coeliac disease. Best Pract. Res. Clin. Gastroenterol.19(3), 413–424 (2005).
  • Cellier C, Delabesse E, Helmer C et al. Refractory sprue, coeliac disease, and enteropathy-associated T-cell lymphoma. French Coeliac Disease Study Group. Lancet356(9225), 203–208 (2000).
  • Wahab PJ, Meijer JW, Goerres MS et al. Coeliac disease: changing views on gluten-sensitive enteropathy. Scand. J. Gastroenterol. (236 Suppl.), 60–65 (2002).
  • Biagi F, Corazza GR. Defining gluten refractory enteropathy. Eur. J. Gastroenterol. Hepatol.13(5), 561–565 (2001).
  • Al-Toma A, Verbeek WH, Hadithi M et al. Survival in refractory coeliac disease and enteropathy associated T cell lymphoma: retrospective evaluation of single centre experience. Gut57, 1373–1378 (2007).
  • Al-Toma A, Visser OJ, van Roessel HM et al. Autologous hematopoietic stem cell transplantation in refractory celiac disease with aberrant T cells. Blood109(5), 2243–2249 (2007).
  • When is a coeliac a coeliac? Report of a working group of the United European Gastroenterology Week in Amsterdam. Eur. J. Gastroenterol. Hepatol. (3), 1123–1128 (2001).
  • Patey-Mariaud De SN, Cellier C, Jabri B et al. Distinction between coeliac disease and refractory sprue: a simple immunohistochemical method. Histopathology37(1), 70–77 (2000).
  • Cellier C, Patey N, Mauvieux L et al. Abnormal intestinal intraepithelial lymphocytes in refractory sprue. Gastroenterology114(3), 471–481 (1998).
  • Carbonnel F, Grollet-Bioul L, Brouet JC et al. Are complicated forms of celiac disease cryptic T-cell lymphomas? Blood92(10), 3879–3886 (1998).
  • Daum S, Hummel M, Weiss D et al. Refractory sprue syndrome with clonal intraepithelial lymphocytes evolving into overt enteropathy-type intestinal T-cell lymphoma. Digestion62(1), 60–65 (2000).
  • Koning F, Schuppan D, Cerf-Bensussan N et al. Pathomechanisms in celiac disease. Best Pract. Res. Clin. Gastroenterol.19(3), 373–387 (2005).
  • Maiuri L, Ciacci C, Ricciardelli I et al. Association between innate response to gliadin and activation of pathogenic T cells in coeliac disease. Lancet362(9377), 30–37 (2003).
  • Hue S, Mention JJ, Monteiro RC et al. A direct role for NKG2D/MICA interaction in villous atrophy during celiac disease. Immunity21(3), 367–377 (2004).
  • Meresse B, Chen Z, Ciszewski C et al. Coordinated induction by IL15 of a TCR-independent NKG2D signaling pathway converts CTL into lymphokine-activated killer cells in celiac disease. Immunity21(3), 357–366 (2004).
  • Mention JJ, Ben AM, Begue B et al. Interleukin 15: a key to disrupted intraepithelial lymphocyte homeostasis and lymphomagenesis in celiac disease. Gastroenterology125(3), 730–745 (2003).
  • Di Sabatino SA, Ciccocioppo R, Cupelli F et al. Epithelium derived interleukin 15 regulates intraepithelial lymphocyte Th1 cytokine production, cytotoxicity, and survival in coeliac disease. Gut55(4), 469–477 (2006).
  • Verbeek WH, Goerres MS, von Blomberg BM et al. Flow cytometric determination of aberrant intra-epithelial lymphocytes predicts T-cell lymphoma development more accurately than T-cell clonality analysis in refractory celiac disease. Clin. Immunol.126(1), 48–56 (2008).
  • Bhagat G, Naiyer AJ, Shah JG et al. Small intestinal D8TCRγ/δNKG2A intraepithelial lymphocytes have attributes of regulatory cells in patients with celiac disease. J. Clin. Invest.118(1), 281–293 (2008).
  • Sollid LM, Markussen G, Ek J et al. Evidence for a primary association of celiac disease to a particular HLA-DQ α/β heterodimer. J. Exp. Med.169(1), 345–350 (1989).
  • Polvi A, Arranz E, Fernandez-Arquero M et al. HLA-DQ2-negative celiac disease in Finland and Spain. Hum. Immunol.59(3), 169–175 (1998).
  • Sollid LM. Molecular basis of celiac disease. Annu. Rev. Immunol.18, 53–81 (2000).
  • Vader W, Stepniak D, Kooy Y et al. The HLA-DQ2 gene dose effect in celiac disease is directly related to the magnitude and breadth of gluten-specific T cell responses. Proc. Natl Acad. Sci. USA100(21), 12390–12395 (2003).
  • Louka AS, Nilsson S, Olsson M et al. HLA in coeliac disease families: a novel test of risk modification by the ‘other’ haplotype when at least one DQA1*05-DQB1*02 haplotype is carried. Tissue Antigens60(2), 147–154 (2002).
  • Zubillaga P, Vidales MC, Zubillaga I et al. HLA-DQA1 and HLA-DQB1 genetic markers and clinical presentation in celiac disease. J. Pediatr. Gastroenterol. Nutr.34(5), 548–554 (2002).
  • Congia M, Cucca F, Frau F et al. A gene dosage effect of the DQA1*0501/DQB1*0201 allelic combination influences the clinical heterogeneity of celiac disease. Hum. Immunol.40(2), 138–142 (1994).
  • Al-Toma A, Goerres MS, Meijer JW et al. Human leukocyte antigen-DQ2 homozygosity and the development of refractory celiac disease and enteropathy-associated T-cell lymphoma. Clin. Gastroenterol. Hepatol.4(3), 315–319 (2006).
  • Holmes GK, Prior P, Lane MR et al. Malignancy in coeliac disease – effect of a gluten free diet. Gut30(3), 333–338 (1989).
  • Hadithi M, von Blomberg BM, Crusius JB et al. Accuracy of serologic tests and HLA-DQ typing for diagnosing celiac disease. Ann. Intern. Med.147(5), 294–302 (2007).
  • Greco L, Romino R, Coto I et al. The first large population based twin study of coeliac disease. Gut50(5), 624–628 (2002).
  • Bevan S, Popat S, Braegger CP et al. Contribution of the MHC region to the familial risk of coeliac disease. J. Med. Genet.36(9), 687–690 (1999).
  • Monsuur AJ, de Bakker PI, Alizadeh BZ et al. Myosin IXB variant increases the risk of celiac disease and points toward a primary intestinal barrier defect. Nat. Genet.37(12), 1341–1344 (2005).
  • Hunt KA, Monsuur AJ, McArdle WL et al. Lack of association of MYO9B genetic variants with coeliac disease in a British cohort. Gut55(7), 969–972 (2006).
  • Amundsen SS, Monsuur AJ, Wapenaar MC et al. Association analysis of MYO9B gene polymorphisms with celiac disease in a Swedish/Norwegian cohort. Hum. Immunol.67(4–5), 341–345 (2006).
  • Giordano M, Marano C, Mellai M et al. A family-based study does not confirm the association of MYO9B with celiac disease in the Italian population. Genes Immun.7(7), 606–608 (2006).
  • Nunez C, Marquez A, Varade J et al. No evidence of association of the MYO9B polymorphisms with celiac disease in the Spanish population. Tissue Antigens68(6), 489–492 (2006).
  • Sanchez E, Alizadeh BZ, Valdigem G et al.MYO9B gene polymorphisms are associated with autoimmune diseases in Spanish population. Hum. Immunol.68(7), 610–615 (2007).
  • Koskinen LL, Korponay-Szabo IR, Viiri K et al. Myosin IXB gene region and gluten intolerance: linkage to coeliac disease and a putative dermatitis herpetiformis association. J. Med. Genet. (2007) (Epub ahead of print).
  • Wolters VM, Verbeek WH, Zhernakova A et al. The MYO9B gene is a strong risk factor for developing refractory celiac disease. Clin. Gastroenterol. Hepatol.5(12), 1399–1405, 1405 (2007).
  • van Heel DA, Franke L, Hunt KA et al. A genome-wide association study for celiac disease identifies risk variants in the region harboring IL2 and IL21. Nat. Genet.39(7), 827–829 (2007).
  • Halstensen TS, Scott H, Brandtzaeg P. Intraepithelial T cells of the TcR γ/δ+ CD8- and V δ 1/J δ 1+ phenotypes are increased in coeliac disease. Scand. J. Immunol.30(6), 665–672 (1989).
  • Savilahti E, Arato A, Verkasalo M. Intestinal γ/δ receptor-bearing T lymphocytes in celiac disease and inflammatory bowel diseases in children. Constant increase in celiac disease. Pediatr. Res.28(6), 579–581 (1990).
  • Kutlu T, Brousse N, Rambaud C et al. Numbers of T cell receptor (TCR) α/β+ but not of TcR γ/δ+ intraepithelial lymphocytes correlate with the grade of villous atrophy in coeliac patients on a long term normal diet. Gut34(2), 208–214 (1993).
  • Jarvinen TT, Kaukinen K, Laurila K et al. Intraepithelial lymphocytes in celiac disease. Am. J. Gastroenterol.98(6), 1332–1337 (2003).
  • Maki M, Holm K, Collin P et al. Increase in γ/δ T cell receptor bearing lymphocytes in normal small bowel mucosa in latent coeliac disease. Gut32(11), 1412–1414 (1991).
  • Sturgess R, Kontakou M, Nelufer J et al. γ/δ T-cell receptor expression in the jejunal epithelium of patients with dermatitis herpetiformis and coeliac disease. Clin. Exp. Dermatol.18(4), 318–321 (1993).
  • Trejdosiewicz LK, Calabrese A, Smart CJ et al. γ/δ T cell receptor-positive cells of the human gastrointestinal mucosa: occurrence and V region gene expression in Heliobacter pylori-associated gastritis, coeliac disease and inflammatory bowel disease. Clin. Exp. Immunol.84(3), 440–444 (1991).
  • Marsh MN. Gluten, major histocompatibility complex, and the small intestine. A molecular and immunobiologic approach to the spectrum of gluten sensitivity (‘celiac sprue’). Gastroenterology102(1), 330–354 (1992).
  • Rostami K, Kerckhaert J, Tiemessen R et al. Sensitivity of antiendomysium and antigliadin antibodies in untreated celiac disease: disappointing in clinical practice. Am. J. Gastroenterol.94(4), 888–894 (1999).
  • Rostom A, Dube C, Cranney A et al. The diagnostic accuracy of serologic tests for celiac disease: a systematic review. Gastroenterology128(4 Suppl. 1), S38–S46 (2005).
  • Collin P, Maki M, Keyrilainen O et al. Selective IgA deficiency and coeliac disease. Scand. J. Gastroenterol.27(5), 367–371 (1992).
  • Abrams JA, Diamond B, Rotterdam H et al. Seronegative celiac disease: increased prevalence with lesser degrees of villous atrophy. Dig. Dis. Sci.49(4), 546–550 (2004).
  • Vahedi K, Mascart F, Mary JY et al. Reliability of antitransglutaminase antibodies as predictors of gluten-free diet compliance in adult celiac disease. Am. J. Gastroenterol.98(5), 1079–1087 (2003).
  • Peters JH, Wierdsma NJ, Teerlink T et al. Poor diagnostic accuracy of a single fasting plasma citrulline concentration to assess intestinal energy absorption capacity. Am. J. Gastroenterol.102(12), 2814–2819 (2007).
  • Isaacson PG, Wright DH, Ralfkiaer E. Enteropathy-type T-cell lymphoma. In: Classification of tumours: pathology and Genetics of tumours of hematopoietic and lymphoid tissues. Jaffe ES, Harris NL, Stein H et al (Eds). IARC Press, Lyon, France 208–209 (2001).
  • Bagdi E, Diss TC, Munson P et al. Mucosal intra-epithelial lymphocytes in enteropathy-associated T-cell lymphoma, ulcerative jejunitis, and refractory celiac disease constitute a neoplastic population. Blood94(1), 260–264 (1999).
  • Goerres MS, Meijer JW, Wahab PJ et al. Azathioprine and prednisone combination therapy in refractory coeliac disease. Aliment. Pharmacol. Ther.18(5), 487–494 (2003).
  • Al-Toma A, Goerres MS, Meijer JW et al. Cladribine therapy in refractory celiac disease with aberrant T cells. Clin. Gastroenterol. Hepatol.4(11), 1322–1327 (2006).
  • Al-Toma A, Verbeek WH, Visser OJ et al. Disappointing outcome of autologous stem cell transplantation for enteropathy-associated T-cell lymphoma. Dig. Liver Dis.39(7), 634–641 (2007).
  • Daum S, Weiss D, Hummel M et al. Frequency of clonal intraepithelial T lymphocyte proliferations in enteropathy-type intestinal T cell lymphoma, coeliac disease, and refractory sprue. Gut49(6), 804–812 (2001).
  • Yamamoto H, Sekine Y, Sato Y et al. Total enteroscopy with a nonsurgical steerable double-balloon method. Gastrointest. Endosc.53(2), 216–220 (2001).
  • Hadithi M, Al-Toma A, Oudejans J et al. The value of double-balloon enteroscopy in patients with refractory celiac disease. Am. J. Gastroenterol.102(5), 987–996 (2007).
  • Ashton-Key M, Diss TC, Pan L et al. Molecular analysis of T-cell clonality in ulcerative jejunitis and enteropathy-associated T-cell lymphoma. Am. J. Pathol.151(2), 493–498 (1997).
  • Mallant M, Hadithi M, Al-Toma AB et al. Abdominal computed tomography in refractory coeliac disease and enteropathy associated T-cell lymphoma. World J. Gastroenterol.13(11), 1696–1700 (2007).
  • Tomei E, Diacinti D, Marini M et al. Abdominal CT findings may suggest coeliac disease. Dig. Liver Dis.37(6), 402–406 (2005).
  • van Weyenberg SJB, Mallant M, Al-Toma A, Jacobs MA, Mulder CJ, Waesberghe JH. Magnetic Resonance Enteroclysis in adult coeliac disease: findings and comparisons between subtypes with different prognosis. OP-G-239 Gut56(Suppl.3), A56 (2007).
  • Hadithi M, Mallant M, Oudejans J et al. 18F-FDG PET versus CT for the detection of enteropathy-associated T-cell lymphoma in refractory celiac disease. J. Nucl. Med.47(10), 1622–1627 (2006).
  • Longstreth GF. Successful treatment of refractory sprue with cyclosporine. Ann. Intern. Med.119(10), 1014–1016 (1993).
  • Wahab PJ, Crusius JB, Meijer JW et al. Cyclosporin in the treatment of adults with refractory coeliac disease – an open pilot study. Aliment. Pharmacol. Ther.14(6), 767–774 (2000).
  • Mulder CJ, Wahab PJ, Meijer JW et al. A pilot study of recombinant human interleukin-10 in adults with refractory coeliac disease. Eur. J. Gastroenterol. Hepatol.13(10), 1183–1188 (2001).
  • Maurino E, Niveloni S, Chernavsky A et al. Azathioprine in refractory sprue: results from a prospective, open-label study. Am. J. Gastroenterol.97(10), 2595–2602 (2002).
  • Daum S, Ipczynski R, Heine B et al. Therapy with budesonide in patients with refractory sprue. Digestion73(1), 60–68 (2006).
  • Gillett HR, Arnott ID, McIntyre M et al. Successful infliximab treatment for steroid-refractory celiac disease: a case report. Gastroenterology122(3), 800–805 (2002).
  • Turner SM, Moorghen M, Probert CS. Refractory coeliac disease: remission with infliximab and immunomodulators. Eur. J. Gastroenterol. Hepatol.17(6), 667–669 (2005).
  • Goodman GR, Burian C, Koziol JA et al. Extended follow-up of patients with hairy cell leukemia after treatment with cladribine. J. Clin. Oncol.21(5), 891–896 (2003).
  • Dray X, Joly F, Lavergne-Slove A et al. A severe but reversible refractory sprue. Gut55(8), 1210–1211 (2006).
  • Vivas S, Ruiz de Morales JM, Ramos F et al. Alemtuzumab for refractory celiac disease in a patient at risk for enteropathy-associated T-cell lymphoma. N. Engl. J. Med.354(23), 2514–2515 (2006).
  • Verbeek WH, Mulder CJ, Zweegman S. Alemtuzumab for refractory celiac disease. N. Engl. J. Med.355(13), 1396–1397 (2006).
  • Dearden CE, Matutes E, Cazin B et al. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. Blood98(6), 1721–1726 (2001).
  • Dearden CE, Matutes E. Alemtuzumab in T-cell lymphoproliferative disorders. Best Pract. Res. Clin. Haematol.19(4), 795–810 (2006).
  • Catassi C, Fabiani E, Corrao G et al. Risk of non-Hodgkin lymphoma in celiac disease. JAMA287(11), 1413–1419 (2002).
  • Catassi C, Bearzi I, Holmes GK. Association of celiac disease and intestinal lymphomas and other cancers. Gastroenterology128(4 Suppl. 1), S79–S86 (2005).
  • Egan LJ, Walsh SV, Stevens FM et al. Celiac-associated lymphoma. A single institution experience of 30 cases in the combination chemotherapy era. J. Clin. Gastroenterol.21(2), 123–129 (1995).
  • Daum S, Ullrich R, Heise W et al. Intestinal non-Hodgkin’s lymphoma: a multicenter prospective clinical study from the German Study Group on Intestinal non-Hodgkin’s Lymphoma. J. Clin. Oncol.21(14), 2740–2746 (2003).
  • Bishton MJ, Haynes AP. Combination chemotherapy followed by autologous stem cell transplant for enteropathy-associated T cell lymphoma. Br. J. Haematol.136(1), 111–113 (2007).
  • van Besien KW, Mehra RC, Giralt SA et al. Allogeneic bone marrow transplantation for poor-prognosis lymphoma: response, toxicity and survival depend on disease histology. Am. J. Med.100(3), 299–307 (1996).
  • Vitolo U, Cortellazzo S, Liberati AM et al. Intensified and high-dose chemotherapy with granulocyte colony-stimulating factor and autologous stem-cell transplantation support as first-line therapy in high-risk diffuse large-cell lymphoma. J. Clin. Oncol.15(2), 491–498 (1997).
  • Hosing C, Saliba RM, McLaughlin P et al. Long-term results favor allogeneic over autologous hematopoietic stem cell transplantation in patients with refractory or recurrent indolent non-Hodgkin’s lymphoma. Ann. Oncol.14(5), 737–744 (2003).
  • Doocey RT, Toze CL, Connors JM et al. Allogeneic haematopoietic stem-cell transplantation for relapsed and refractory aggressive histology non-Hodgkin lymphoma. Br. J. Haematol.131(2), 223–230 (2005).
  • Gallamini A, Zaja F, Patti C et al. Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood110(7), 2316–2323 (2007).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.